Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 20/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4074464 | 0.93 | HTR6 (0.58) | HTR6 | |
| SCHEMBL4819209 | 0.85 | HTR6 (0.50) | HTR6 | |
| SCHEMBL4069815 | 0.84 | HTR6 (0.45) | HTR6 | |
| SCHEMBL4075071 | 0.84 | HTR6 (0.56) | HTR6 | |
| SCHEMBL4076469 | 0.82 | HTR6 (0.52) | HTR6 | |
| SCHEMBL4072754 | 0.80 | HTR6 (0.52) | HTR6 | |
| SCHEMBL4068821 | 0.80 | HTR6 (0.61) | HTR6 | |
| SCHEMBL4072753 | 0.80 | HTR6 (0.52) | HTR6 | |
| SCHEMBL4077620 | 0.80 | HTR6 (0.52) | HTR6 | |
| SCHEMBL4077566 | 0.79 | HTR6 (0.56) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325992-A1 | COMPOUND HAVING CYCLIC GROUP BOUND THERETO THROUGH SPIRO BINDING AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
| US-7589108-B2 | 1-Heterocyclylalkyl-3-sulfonylindole or -indazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2009-09-15 | — | — | US | disclosed |
| EP-2055705-A1 | COMPOUND HAVING CYCLIC GROUP BOUND THERETO THROUGH SPIRO BINDING AND USE THEREOF | Ono Pharmaceutical CO., LTD. (JP) | 2009-05-06 | — | — | EP | disclosed |
| US-20060030593-A1 | 1-Heterocyclylalkyl-3-sulfonylindole or -indazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2006-02-09 | — | — | US | disclosed |
| US-6995176-B2 | 1-heterocyclylalkyl-3-sulfonyl-indole or -indazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2006-02-07 | — | — | US | disclosed |
| US-20040024023-A1 | 1-Heterocyclylalkyl-3-sulfonyl-indole or -indazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH | 2004-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030593-A1 | 1-Heterocyclylalkyl-3-sulfonylindole or -indazole derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR3A, HTR5A | HTR6 1/4885 |
| US-20090325992-A1 | COMPOUND HAVING CYCLIC GROUP BOUND THERETO THROUGH SPIRO BINDING AND USE THEREOF | CXCR4, CXCL12, CXCR1 | HTR6 1421/4885 |
| US-20040024023-A1 | 1-Heterocyclylalkyl-3-sulfonyl-indole or -indazole derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR3A, HTR1A | HTR6 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.